title: Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies.
abstract: BACKGROUND
  It remains unclear whether the hemodilution effect of body mass index (BMI) on PSA levels translates to inappropriate prostate cancer (PCa) screening in obese men. To address this, we conducted two nested case-control studies within prospective cohorts of men undergoing radical prostatectomy for newly diagnosed PCa.
  
  
  METHODS
  We identified 1817 men with BMI 30 kg m(-2) (cases) and 1244 men with BMI <25 kg m(-2) (controls) who underwent surgery to treat PCa at Mayo Clinic in Rochester between 2000 and 2009. Cases and controls were frequency matched on age and PSA level. In a similar manner, we identified 206 cases and 133 controls treated at Mayo Clinic in Florida between 2006 and 2011. We employed logistic regression models to evaluate the association of pathologic features of aggressiveness with obesity status.
  
  
  RESULTS
  After adjusting for age and PSA level, we noted that obese men in the Rochester population are more likely to present with Gleason grade 8-10 tumors (OR= 1.50; 95% CI 1.14-1.96; P=0.003) and pT3, pT4, pTxN+ stage disease (OR=1.30; 95% CI 1.05-1.62). We noted a similar association seminal vesicle involvement (OR= 1.41; 95% CI 1.03-1.92; P=0.03). Results from the smaller Florida population supported these same associations but did not achieve conventional statistical significance.
  
  
  CONCLUSIONS
  Obese men present with more aggressive PCa tumors compared with non-obese men of similar age and PSA screening values. If confirmed, this would support the need to explore PSA-based screening in obese men to possibly account for a hemodilution effect.
authors: Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.
authors: A S
authors: AS
authors: Parker
authors: D D
authors: DD
authors: Thiel
authors: E
authors: E
authors: Bergstralh
authors: R E
authors: RE
authors: Carlson
authors: L J
authors: LJ
authors: Rangel
authors: R W
authors: RW
authors: Joseph
authors: N
authors: N
authors: Diehl
authors: R J
authors: RJ
authors: Karnes
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D016022:Case-Control Studies; D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009765:Obesity / Q000150:complications*; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000150:complications* / Q000378:metabolism / Q000473:pathology* / Q000601:surgery
chemical_list: D017430:Prostate-Specific Antigen
references: World J Urol. 2014 Apr;32(2):323-8
references: 22847453
references: JAMA. 2007 Nov 21;298(19):2275-80
references: 18029831
references: Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):748-51
references: 19258472
references: Cancer. 2007 Feb 15;109(4):675-84
references: 17211863
references: Epidemiol Rev. 2007;29:88-97
references: 17478439
references: N Engl J Med. 2009 Mar 26;360(13):1351-4
references: 19297564
references: Urology. 2011 Oct;78(4):868-72
references: 21843902
references: Urology. 2010 Nov;76(5):1268.e1-6
references: 20739049
references: Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):331-6
references: 19124516
references: Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2343; author reply 2343-4
references: 19661096
references: Nat Clin Pract Urol. 2007 Nov;4(11):605-14
references: 17982437
references: Urology. 2010 Mar;75(3):648-52
references: 19854477
references: Ann Epidemiol. 2000 Aug;10(6):361-9
references: 10964002
references: Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1977-83
references: 17035408
references: BJU Int. 2009 Nov;104(10):1457-61
references: 19522868
references: Prostate. 2008 Mar 1;68(4):373-80
references: 18189231
references: Am J Med. 2010 Sep;123(9):829-35
references: 20800152
references: Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):63-9
references: 17179486
references: Am J Clin Oncol. 2012 Oct;35(5):490-2
references: 21577087